28 Apr 2026 · to Health
Deputy Martin Daly asked the Minister for Health her views on whether the ongoing delay in concluding reimbursement negotiations for skyclarys for patients with Friedreich’s ataxia is consistent with the commitment to “equitable access” set out in the recently launched National Rare Disease Strategy
23 Apr 2026 · to Health
Deputy Eoghan Kenny asked the Minister for Health if her Department has considered the inclusion of skyclarys (omaveloxolone) which is a treatment for Friedreich's ataxia in a reimbursement scheme given the cost of the drug and the fact that other European countries provide this scheme to patients
22 Apr 2026 · to Health
will review matters raised in correspondence (details supplied); if she will provide an update on the HSE's decision regarding the reimbursement of skyclarys for the treatment of Friedreich's ataxia; if she will note that 619 days have elapsed since the application for reimbursement was submitted
22 Apr 2026 · to Health
Deputy Ken O'Flynn asked the Minister for Health whether an application has been received for the reimbursement of the drug skyclarys for the treatment of Friedreich’s ataxia; if so, the current status of that application; the date on which it was submitted to the National Centre
22 Apr 2026 · to Health
pathways are currently available in the State for patients with Friedreich’s ataxia; and whether consideration is being given to enabling access to skyclarys pending a full reimbursement decision. [29080/26
22 Apr 2026 · to Health
Deputy Ken O'Flynn asked the Minister for Health whether skyclarys has been approved or reimbursed in other EU Member States or comparable jurisdictions; and whether such decisions are considered in Ireland’s reimbursement process. [29083/26
21 Apr 2026 · to Health
Deputy Catherine Callaghan asked the Minister for Health for an update on the measures being taken to provide treatments such as skyclarys (omaveloxolone) to patients with Friedrich's ataxia in Carlow and Kilkenny, and across the country; and if she will make a statement on the matter. [28381/26
21 Apr 2026 · to Health
Deputy Micheál Carrigy asked the Minister for Health for an update on the price negotiations regarding Skyclarys; the steps being taken to support those with Friedrich’s ataxia in the time critical interim; and if she will make a statement on the matter. [28226/26
21 Apr 2026 · to Health
Deputy James Geoghegan asked the Minister for Health if the drug skyclarys (omaveloxolone) used for the treatment of Friedreich's ataxia will be made available under licence in Ireland; and if she will make a statement on the matter. [28209/26
16 Apr 2026 · to Health
Deputy Natasha Newsome Drennan asked the Minister for Health to ensure that the HSE urgently prioritises a conclusion to the skyclarys reimbursement negotiations, given that it is the only available treatment for this progressive disease, which currently can be classed as having an ‘unmet need’ as outlined
15 Apr 2026 · to Health
Deputy Emer Currie asked the Minister for Health the latest update on the accessibility of skyclarys for the treatment of Friedreich’s ataxia; the timeline as to when the HSE senior leadership team will make a decision; and if she will make a statement on the matter. [27367/26
15 Apr 2026 · to Health
Peter 'Chap' Cleere asked the Minister for Health if she will intervene to ensure that the HSE urgently prioritises a conclusion to the skyclarys reimbursement negotiations, given that it is the only available treatment for this progressive disease, which currently can be classed as having an 'unmet need
15 Apr 2026 · to Health
Deputy Peter 'Chap' Cleere asked the Minister for Health her views on way in which the current delay with the skyclarys reimbursement negotiations aligns with the equitable access promised in the newly launched National Rare Disease Strategy 2025-2030. [27405/26
14 Apr 2026 · to Health
Deputy Denise Mitchell asked the Minister for Health if consideration will be given to adding the drug skyclarys which is used in the treatment of Friedreich's ataxia to the drugs payment scheme; and if she will make a statement on the matter. [25182/26
14 Apr 2026 · to Health
Deputy Tom Brabazon asked the Minister for Health if the HSE will fund the skyclarys drug for those suffering from Friedreich's ataxia. [26084/26
14 Apr 2026 · to Health
Deputy Holly Cairns asked the Minister for Health if a decision not to reimburse a treatment Omaveloxolone sold under the brand name Skyclarys will be reviewed given it is the only pharmaceutical treatment available for treating Friedreich's Ataxia; and if she will make a statement
14 Apr 2026 · to Health
Deputy Pat Buckley asked the Minister for Health if she will ensure that the HSE urgently prioritizes a conclusion to the skyclarys reimbursement negotiations, given that it is the only available treatment for Friedreich's ataxia, which currently can be classed as having an ‘unmet need’ as outlined
14 Apr 2026 · to Health
Deputy Ruth Coppinger asked the Minister for Health if she will take steps to ensure that skyclarys (omaveloxolone) is made available for those with Fredericks ataxia who require it; and if she will make a statement on the matter. [26512/26
14 Apr 2026 · to Health
Parliamentary Question No.1818 of 18 March 2026, if she will intervene to ensure that the HSE urgently prioritises a conclusion to the skyclarys reimbursement negotiations, given that it is the only available treatment for this progressive disease, which currently can be classed as having an 'unmet need
14 Apr 2026 · to Health
being taken to ensure the HSE considers the time-critical nature of the 2026 IPHA Framework Agreement during the current price negotiations for Skyclarys; and the way in which the commitments in the National Rare Disease Strategy 2025-2030 and the 2026 IPHA Framework Agreement, which aims
14 Apr 2026 · to Health
Deputy Robert O'Donoghue asked the Minister for Health if she will intervene to ensure that the HSE urgently concludes reimbursement negotiations for skyclarys given that it is currently the only available treatment for Friedreich’s ataxia and that the condition may be considered an unmet need under
14 Apr 2026 · to Health
Deputy Robert O'Donoghue asked the Minister for Health to provide a clear timeline for the conclusion of the reimbursement process for skyclarys given that more than 80 Parliamentary Questions have already been raised on this matter without any indication of when a decision may be reached
25 Mar 2026 · to Health
steps are being taken to ensure the HSE recognises the “time-critical” nature of Friedreich’s ataxia during the current price negotiations for skyclarys; and if she will make a statement on the matter. [22549/26
24 Mar 2026 · to Health
Michael Collins asked the Minister for Health if she will intervene to ensure the HSE prioritises a conclusion to the reimbursement negotiations for skyclarys, given it is the only available treatment for Friedreich’s ataxia and the unmet clinical need recognised in the national rare disease strategy
24 Mar 2026 · to Health
Deputy Michael Collins asked the Minister for Health her views on whether current delays in providing skyclarys are compatible with the commitment to “equitable access” outlined in the new National Rare Disease Strategy, particularly when patients across Europe already have access to this therapy; and if she will